Last reviewed · How we verify

DTaP-IPV combination vaccine

Boryung Biopharma Co., Ltd. · Phase 3 active Biologic

DTaP-IPV combination vaccine is a Combination vaccine Biologic drug developed by Boryung Biopharma Co., Ltd.. It is currently in Phase 3 development for Prevention of diphtheria, tetanus, pertussis, and poliomyelitis in infants and children.

This combination vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, and poliovirus by delivering inactivated toxins and viral antigens.

This combination vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, and poliovirus by delivering inactivated toxins and viral antigens. Used for Prevention of diphtheria, tetanus, pertussis, and poliomyelitis in infants and children.

At a glance

Generic nameDTaP-IPV combination vaccine
SponsorBoryung Biopharma Co., Ltd.
Drug classCombination vaccine
ModalityBiologic
Therapeutic areaImmunology
PhasePhase 3

Mechanism of action

DTaP-IPV is a quadrivalent vaccine combining diphtheria and tetanus toxoids, acellular pertussis antigen, and inactivated poliovirus. It works by presenting these antigens to the immune system, triggering both humoral (antibody) and cell-mediated immune responses that provide protective immunity against these four infectious diseases. The vaccine prevents disease by enabling rapid immune recognition and neutralization of the pathogens upon natural exposure.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about DTaP-IPV combination vaccine

What is DTaP-IPV combination vaccine?

DTaP-IPV combination vaccine is a Combination vaccine drug developed by Boryung Biopharma Co., Ltd., indicated for Prevention of diphtheria, tetanus, pertussis, and poliomyelitis in infants and children.

How does DTaP-IPV combination vaccine work?

This combination vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, and poliovirus by delivering inactivated toxins and viral antigens.

What is DTaP-IPV combination vaccine used for?

DTaP-IPV combination vaccine is indicated for Prevention of diphtheria, tetanus, pertussis, and poliomyelitis in infants and children.

Who makes DTaP-IPV combination vaccine?

DTaP-IPV combination vaccine is developed by Boryung Biopharma Co., Ltd. (see full Boryung Biopharma Co., Ltd. pipeline at /company/boryung-biopharma-co-ltd).

What drug class is DTaP-IPV combination vaccine in?

DTaP-IPV combination vaccine belongs to the Combination vaccine class. See all Combination vaccine drugs at /class/combination-vaccine.

What development phase is DTaP-IPV combination vaccine in?

DTaP-IPV combination vaccine is in Phase 3.

What are the side effects of DTaP-IPV combination vaccine?

Common side effects of DTaP-IPV combination vaccine include Injection site pain, redness, or swelling, Fever, Irritability or fussiness, Drowsiness, Loss of appetite.

Related